Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Multiple Myeloma Clinical Trial

— wCCyd  

Official title:

A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01857115
• Other study ID #: IST-CAR-561
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: April 2013
• Est. completion date: September 2024

Study information

• Verified date: February 2024
• Source: Stichting European Myeloma Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.

Description:

TREATMENT PERIOD Patients will start the induction treatment with wCCyd, as soon as the screening visits of the pre-treatment period have been terminated.

Each cycle will be repeated every 28 days for a total of 9 courses.

Treatment schedule for 9 cycles of induction:

Phase I:

In the phase I part of the study, the following dose levels of carfilzomib will be studied with constant doses of dexamethasone and cyclophosphamide to define the maximum tolerated dose (MTD):

Level -1

1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.

2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.

3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 36 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).

Level 0 (starting dose)

1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.

2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.

3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 45 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 45 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).

Level +1

1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.

2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.

3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 56 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 56 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).

Level +2

1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.

2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.

3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).

Patients will be observed during the first cycle of therapy for the assessment of side effects and observation of DLTs. Dose escalation will proceed as follows:

• 3 patients will be entered at dose level 0.

• If 0/3 patients experience DLT, dose escalation will continue.

• If 1/3 patients experience DLT, 3 additional patients will be added to this cohort (max 6).

• If no further patients experience DLT (1/6) dose escalation will continue.

• If 2/6 patients experience DLT, the MTD will have been exceeded and the MTD will be the previous dose at which < 2/6 experienced DLT.

• If 2/3 patients experience a DLT at any given dose, the MTD will have been exceeded and the MTD will be the preceding dose at which < 2/6 (or 1/3) patients experienced a DLT.

Phase II:

The dose used to treat patients in the phase II will be the MTD defined in the phase I of the study.

MAINTENANCE PERIOD At the end of the induction phase, patients will start the maintenance phase with Carfilzomib at the MTD defined by the phase I study IV once daily on days 1, 8, 15 until progression or intolerance.

Treatment schedule for maintenance until progression or intolerance:

Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 63
• Est. completion date: September 2024
• Est. primary completion date: November 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 99 Years

Eligibility

Inclusion Criteria:

Disease-related

1. Patient is a newly diagnosed MM patient.

2. Patient is age = 65 year of age or who are ineligible for autologous stem cell transplantation.

3. Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, = 0.5 g/dL of M-protein) and, where applicable, urine light-chain excretion of > 200 mg/24 hours. For patients with oligo- or non-secretory MM, it is required that they have measurable plasmacytoma > 2 cm as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or an abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that less than 10% of patients admitted to this study will be oligo- or non-secretory MM with free light chains only in order to maximize interpretation of benefit results.

Demographic:

4. Age = 18 years.

5. Life expectancy = 3 months.

6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix F).

Laboratory:

7. Adequate hepatic function, with serum ALT = 3.5 times the upper limit of normal and serum direct bilirubin = 2 mg/dL (34 µmol/L) within 14 days prior to randomization.

8. Absolute neutrophil count (ANC) = 1.0 × 109/L within 14 days prior to randomization.

9. Corrected serum calcium = 14 mg/dL (3.5 mmol/L).

10. Alanine transaminase (ALT): = 3 x the ULN.

11. Hemoglobin = 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines).

12. Platelet count = 50 × 109/L (= 30 × 109/L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to randomization.

13. Creatinine clearance (CrCl) = 15 mL/minute within 7 days prior to randomization, either measured or calculated using a standard formula (eg, Cockcroft and Gault).

Ethical/Other:

14. Written informed consent in accordance with federal, local, and institutional guidelines.

15. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception.

16. Male subjects must agree to practice contraception.

Exclusion Criteria:

Disease-related:

1. Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid; = to the equivalent of dexamethasone 40 mg/day for 4 days)

2. Patient with relapsed or refractory multiple myeloma.

3. Patients with non-secretory MM unless serum free light chains are present and the ratio is abnormal.

Concurrent Conditions:

4. Pregnant or lactating females (Appendix I).

5. Major surgery within 21 days prior to randomization.

6. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization.

7. Known human immunodeficiency virus infection.

8. Active hepatitis B or C infection.

9. Unstable angina or myocardial infarction within 4 months prior to randomization, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.

10. Uncontrolled hypertension, uncontrolled congestive heart failure (CHF) or uncontrolled diabetes within 14 days prior to randomization.

11. Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.

12. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization.

13. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).

14. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.

15. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.

16. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Carfilzomib

• Cyclophosphamide

• Dexamethasone

Locations

Country	Name	City	State
Italy	Fondazione EMN Italy Onlus	Torino

Sponsors (2)

Lead Sponsor	Collaborator
Stichting European Myeloma Network	Fondazione EMN Italy Onlus

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of Dose-limiting toxicity (DLT)	Non-hematologic: Grade2 neuropathy with pain; any Grade 3 toxicity (excluding nausea, vomiting, diarrhea); Grade3 nausea, vomiting, or diarrhea despite maximal antiemetic/antidiarrheal therapy; Grade4 fatigue lasting for =7days; Any non-hematologic toxicity requiring a dose reduction within Cycle1; Inability to receive Day 1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.; Hematologic: Grade 4 neutropenia (ANC<0.5x109/L) lasting for =7days; Febrile neutropenia (ANC<1.0x109/L with a fever =38.3ºC); Grade 4 thrombocytopenia (platelets<25.0x109/L) lasting =7 days despite dose delay; Grade 3-4 thrombocytopenia associated with bleeding; Any hematologic toxicity requiring a dose reduction within Cycle1; Inability to receive Day1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.	1 year
Primary	Partial Response (PR)	The primary efficacy endpoints will be assessed by considering partial response (PR) following the proposed regimen, at the end of third cycle.	1 year
Secondary	Response rate (RR)	Determine the response rate	3 years
Secondary	Progression free-survival (PFS)	Determine progression free-survival	3 years
Secondary	Time to progression (TTP)	Determine the time to progression	3 years
Secondary	Duration of response (DOR)	Determine the duration of response	3 years
Secondary	Overall survival (OS)	Determine the overall survival	3 years
Secondary	Time to next therapy (TTNT)	Determine the time to next therapy	3 years
Secondary	Responses	Determine whether responses obtained with wCCyd treatment are associated with a prolongation of PFS, in comparison with non-responding patients	3 years
Secondary	Response and survival	Determine whether tumor response and survival might significantly change in particular subgroups of patients defined on prognostic factors (ß2-microglobulin, C-reactive protein (CRP), FISH, gene expression profile)	3 years
Secondary	Maintenance	Determine the benefit on PFS and OS of maintenance with Carfilzomib; Determine the benefit on tumor load of maintenance with Carfilzomib	3 years